Investment Strategy: Biologics LOE For institutional investors, the analytical question at a biologic LOE is not how much will biosimilars capture but rather: (1) what is the net price convergence trajectory between the reference product and biosimilar competitors under real-world formulary conditions, (2) does the innovator have pre-negotiated rebate contracts that lock in formulary position for 12 to 24 months post-launch, (3) what is the IP stack on the successor asset, and (4) how far along is the clinical conversion to a reformulated or combination version that carries fresh exclusivity
95% confidence interval [CI], 0.071 to 0.926
While its effective for these purposes, some people experience side effects, including night sweats
They stated that the weight loss is due to Rybelsus making them feel fuller after a meal.
The fatty acid tail problem The C18 octadecanedioic acid moiety that gives retatrutide its extended half-life through albumin binding also makes the molecule more lipophilic than unmodified peptides
Last year, a Florida judge ruled against Eli Lilly, maker of tirzepatide, the active ingredient in Zepbound, after it tried to use state law to block reformulated versions of the drug
